Tag Archive for ‘pancreatic cancer’
Balancing statistical relevance with clinician experience leads to innovative approaches to patient care.
Modified FOLFIRINOX is superior to gemcitabine as adjuvant therapy for resected pancreatic cancer: The PRODIGE 24/CCTG PA6 Trial
The study design and findings of the PRODIGE 24/CCTG PA6 Trial are outlined, which showed improved survival with modified FOLFIRINOX for resected pancreatic cancer patients.
This news brief highlights a JACS article that examines the results of a distal cholangiocarcinoma and pancreatic cancer multi-institution study.
Pancreatic cancer is the fourth-most common cause of cancer-related death in the U.S. and is predicted to soon be the third-leading cause. Surgical resection with pancreatectomy has historically been viewed as offering the only chance for cure. However, achieving negative margins at surgery can be difficult, with positive surgical margins found in as many as […]
Improving resection rates in borderline resectable pancreatic cancer: Pilot study shows favorable results
The clinical importance of the Alliance A021101 cooperative group study as well as the design of the trial itself are the focus of this month’s column.
This column discusses how multimodality therapy, including surgical resection, now represents a potential route to long-term survival for a group of patients with so-called “borderline resectable” cancers.